Stockreport

Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Gilead Sciences, Inc.  (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
PDF – New Findings Demonstrate 81% of Participants Achieve Durable Biochemical Response by Month 30 with Livdelzi –– Nearly Half of Participants with Primary Biliary Cholang [Read more]